207 related articles for article (PubMed ID: 22253776)
1. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy.
Zhang T; Li SY; Nuermberger EL
PLoS One; 2012; 7(1):e29774. PubMed ID: 22253776
[TBL] [Abstract][Full Text] [Related]
2. Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
Zhang T; Li SY; Converse PJ; Grosset JH; Nuermberger EL
PLoS Negl Trop Dis; 2013; 7(12):e2598. PubMed ID: 24367713
[TBL] [Abstract][Full Text] [Related]
3. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
Zelmer A; Tanner R; Stylianou E; Damelang T; Morris S; Izzo A; Williams A; Sharpe S; Pepponi I; Walker B; Hokey DA; McShane H; Brennan M; Fletcher H
BMC Infect Dis; 2016 Aug; 16():412. PubMed ID: 27519524
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
Zhang N; Strydom N; Tyagi S; Soni H; Tasneen R; Nuermberger EL; Savic RM
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907182
[TBL] [Abstract][Full Text] [Related]
5. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.
Andreu N; Zelmer A; Sampson SL; Ikeh M; Bancroft GJ; Schaible UE; Wiles S; Robertson BD
J Antimicrob Chemother; 2013 Sep; 68(9):2118-27. PubMed ID: 23633686
[TBL] [Abstract][Full Text] [Related]
6. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence.
Andreu N; Fletcher T; Krishnan N; Wiles S; Robertson BD
J Antimicrob Chemother; 2012 Feb; 67(2):404-14. PubMed ID: 22101217
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
8. Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
Brodin P; Majlessi L; Brosch R; Smith D; Bancroft G; Clark S; Williams A; Leclerc C; Cole ST
J Infect Dis; 2004 Jul; 190(1):115-22. PubMed ID: 15195250
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
10. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.
Hickey MJ; Arain TM; Shawar RM; Humble DJ; Langhorne MH; Morgenroth JN; Stover CK
Antimicrob Agents Chemother; 1996 Feb; 40(2):400-7. PubMed ID: 8834887
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
12. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging.
Zelmer A; Carroll P; Andreu N; Hagens K; Mahlo J; Redinger N; Robertson BD; Wiles S; Ward TH; Parish T; Ripoll J; Bancroft GJ; Schaible UE
J Antimicrob Chemother; 2012 Aug; 67(8):1948-60. PubMed ID: 22635525
[TBL] [Abstract][Full Text] [Related]
13. Rapid determination of growth inhibition of Mycobacterium tuberculosis by GC-MS/MS quantitation of tuberculostearic acid.
Cai G; Pauli GF; Wang Y; Jaki BU; Franzblau SG
Tuberculosis (Edinb); 2013 May; 93(3):322-9. PubMed ID: 23454100
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
Lanoix JP; Lenaerts AJ; Nuermberger EL
Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development.
Van Wijk RC; van der Sar AM; Krekels EHJ; Verboom T; Spaink HP; Simonsson USH; van der Graaf PH
Clin Transl Sci; 2020 Nov; 13(6):1060-1064. PubMed ID: 32267997
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis vaccine research: the impact of immunology.
Barker LF; Brennan MJ; Rosenstein PK; Sadoff JC
Curr Opin Immunol; 2009 Jun; 21(3):331-8. PubMed ID: 19505813
[TBL] [Abstract][Full Text] [Related]
17. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
[TBL] [Abstract][Full Text] [Related]
18. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
[TBL] [Abstract][Full Text] [Related]
19. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
20. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
